

Fig. 1




Fig. 1 (continued)




Fig. 2





Fig. 2 (continued)



j




Fig. 3




Fig. 3 (continued)




Fig. 3 (continued)




Fig. 4




Fig. 4 (continued)




Fig. 5




Fig. 6




Fig. 6 (continued)




Fig. 7




Fig. 7 (continued)

Murine WEHI-3B cells mTRAIL-R2 protein (2 MDM2-inhibitors)




Fig. 8




Fig. 9




Fig. 10




Fig. 10




Fig. 10 (continued)




Fig. 11




Fig. 11 (continued)

C




Fig. 12




Fig. 12 (continued)

a (continuation)




Fig. 13




Fig. 14




Fig. 15




Fig. 16




Fig. 16 (continued)

a (continued)




Fig. 17




Fig. 17 (continued)




Fig. 18





Fig. 19

Gating strategy: Primary human AML cells



SUBSTITUTE SHEET (RULE 26)

Fig. 19 (continued)




Fig. 20




Fig. 21

Human primary AML cells from patient #P56

a




Fig. 21

B (first part)


Human primary AML cell enrichment before
ansfer into immunodeficient mice

Fig. 21

b (continuation)




Fig. 22

Human primary AML cells from patient #P57

a




Fig. 22




Fig. 22 (continued)

C




Figure 23 % GFP⁺RFP⁺ OCI-AML3 cells on d0 before transplant:




Fig. 24




Fig. 24 (continued)




Fig. 25




Fig. 26




Fig. 26 (continued)




Fig. 27

Graphical abstract

